Abstract: The invention provides methods for reducing the percentage of body fat, increasing the level of adiponectin, and/or treating or reducing the risk of cardiovascular disease (CVD) and coronary heart disease (CHD). Such methods include administering to an animal or human sufficient levels of a compound comprising a tri blend of HPMC (K15, K100, and K200) and myristic fatty acid.
Abstract: The invention provides methods for reducing the percentage of body fat, increasing the level of adiponectin, and/or treating or reducing the risk of cardiovascular disease (CVD) and coronary heart disease (CHD). Such methods include administering to an animal or human sufficient levels of a compound comprising a tri blend of HPMC (K15, K100, and K200) and myristic fatty acid.
Abstract: The invention provides methods and compositions for reducing the percentage of body fat in an animal or human and increasing the level of adiponectin in an animal or human. Such methods include administering to an animal or human sufficient levels of a compound comprising a tri blend of HPMC (K15, K100, and K200) and myristic fatty acid.
Abstract: The invention provides methods and compositions for reducing the percentage of body fat in an animal or human and increasing the level of adiponectin in an animal or human. Such methods include administering to an animal or human sufficient levels of a compound comprising a tri blend of HPMC (K15, K100, and K200) and myristic fatty acid.